Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Down 52.4% in December

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totaling 36,318 shares, a decline of 52.4% from the December 15th total of 76,298 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average trading volume of 84,243 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 84,243 shares, the short-interest ratio is presently 0.4 days. Currently, 0.8% of the shares of the stock are short sold.

Redhill Biopharma Price Performance

Shares of RDHL remained flat at $1.23 during mid-day trading on Thursday. 16,399 shares of the stock were exchanged, compared to its average volume of 2,632,775. The business’s fifty day moving average price is $1.15 and its 200 day moving average price is $1.47. Redhill Biopharma has a one year low of $0.91 and a one year high of $6.80. The company has a market cap of $6.26 million, a P/E ratio of 0.00 and a beta of 4.87.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Redhill Biopharma in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Redhill Biopharma stock. Gagnon Securities LLC purchased a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned about 0.54% of Redhill Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.